2021
ASO Visual Abstract: Assessing Interobserver Variability of Cosmetic Outcome Assessment in Breast Cancer Patients Undergoing Breast Conservation Surgery
Chagpar A, Berger E, Alperovich M, Zanieski G, Avraham T, Lannin D. ASO Visual Abstract: Assessing Interobserver Variability of Cosmetic Outcome Assessment in Breast Cancer Patients Undergoing Breast Conservation Surgery. Annals Of Surgical Oncology 2021, 28: 632-632. DOI: 10.1245/s10434-021-10584-z.Peer-Reviewed Original Research
2017
Intraoperative Injection of Technetium‐99m Sulfur Colloid for Sentinel Lymph Node Biopsy in Breast Cancer Patients: A Single Institution Experience
Berrocal J, Saperstein L, Grube B, Horowitz NR, Chagpar AB, Killelea BK, Lannin DR. Intraoperative Injection of Technetium‐99m Sulfur Colloid for Sentinel Lymph Node Biopsy in Breast Cancer Patients: A Single Institution Experience. Surgery Research And Practice 2017, 2017: 5924802. PMID: 28492062, PMCID: PMC5406738, DOI: 10.1155/2017/5924802.Peer-Reviewed Original ResearchNonsentinel lymph nodesLymph nodesSentinel lymph nodesIntraoperative injectionSulfur colloidNode biopsySentinel lymphSentinel nodesAdditional positive nonsentinel lymph nodesPositive nonsentinel lymph nodesPositive sentinel lymph nodesSentinel lymph node biopsyLymph node biopsySentinel node biopsySingle institution experienceBreast cancer patientsLong-term resultsAxillary dissectionInstitution experienceMetastatic carcinomaCancer patientsBreast centerMedian numberPatientsBiopsy
2014
Does three-dimensional intraoperative specimen imaging reduce the need for re-excision in breast cancer patients?
Chagpar A, Butler M, Killelea B, Horowitz N, Stavris K, Lannin D. Does three-dimensional intraoperative specimen imaging reduce the need for re-excision in breast cancer patients? Journal Of Clinical Oncology 2014, 32: 107-107. DOI: 10.1200/jco.2014.32.30_suppl.107.Peer-Reviewed Original ResearchMargin statusIntraoperative imagingFinal margin statusMedian tumor sizeBreast cancer patientsRe-excision ratesIntraoperative specimen radiographyCohort of interestIntraoperative marginsResidual tumorPartial mastectomyPositive marginsProspective studyTumor sizeCancer patientsInvasive cancerFurther excisionPathology resultsIntraoperative resectionPatientsDefinitive specimenSpecimen radiographyIntraoperative specimenSurgeons
2013
A pilot chemoprevention study of isopropanolic black cohosh extract in women with ductal carcinoma in situ.
Hofstatter E, Stavris K, Horowitz N, Killelea B, Tsangaris T, Lannin D, Andrejeva L, Cong X, Yao X, Rimm D, Chagpar A. A pilot chemoprevention study of isopropanolic black cohosh extract in women with ductal carcinoma in situ. Journal Of Clinical Oncology 2013, 31: tps1609-tps1609. DOI: 10.1200/jco.2013.31.15_suppl.tps1609.Peer-Reviewed Original ResearchIsopropanolic black cohosh extractBlack cohosh extractBlack cohoshDuctal carcinomaBreast cancerBreast epithelial cell proliferationPre-operative courseTwo-sided significance levelDisease-free survivalLiver function testsBreast cancer preventionSerum hormone levelsAnti-inflammatory effectsBreast cancer patientsPost-menopausal womenCohort of womenRecent preclinical dataSignificant protective effectKi-67 stainingBreast core biopsyLevels of Ki67Years of ageEpithelial cell proliferationWilcoxon signed-rank testEligible subjectsQuantitative Ki-67 score as predictive of response to neoadjuvant chemotherapy in breast cancer.
Brown J, Lannin D, Killelea B, DiGiovanna M, Rimm D. Quantitative Ki-67 score as predictive of response to neoadjuvant chemotherapy in breast cancer. Journal Of Clinical Oncology 2013, 31: 1085-1085. DOI: 10.1200/jco.2013.31.15_suppl.1085.Peer-Reviewed Original ResearchKi-67 expressionPathological complete responseNeoadjuvant chemotherapyKi-67Consecutive invasive breast cancer patientsAQUA scoreInvasive breast cancer patientsAdditional survival benefitBreast cancer patientsKi-67 levelsPre-surgical biopsyKi-67 scoreLikelihood of responseMIB-1 antibodyPrediction of responseNeoadjuvant therapyComplete responseNodal statusSurvival benefitER statusIndependent predictorsMultivariable analysisAdvanced tumorsTumor sizeCancer patients
2012
Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients?
Chagpar A, Neumeister V, Lannin D, Rimm D. Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients? Journal Of Clinical Oncology 2012, 30: 1121-1121. DOI: 10.1200/jco.2012.30.15_suppl.1121.Peer-Reviewed Original ResearchBreast cancer patientsLN statusCancer patientsLymphovascular invasionTumor sizeTumor markersPositive LNsPoor prognosisMedian numberPrimary tumor markersMedian patient ageMedian tumor sizeLymph node positivityLN-positive patientsLymph node statusOnly factorCancer initiating cellsCancer-initiating cellsLevels of CD44Axillary surgeryLN positivityNode positivityPatient agePositive patientsClinicopathologic data
2011
P3-07-26: How Generalizable Is the Patient Population Enrolled in ACOSOG Z11?
Lannin D, Killelea B, Grube B, Horowitz N, Chagpar A. P3-07-26: How Generalizable Is the Patient Population Enrolled in ACOSOG Z11? Cancer Research 2011, 71: p3-07-26-p3-07-26. DOI: 10.1158/0008-5472.sabcs11-p3-07-26.Peer-Reviewed Original ResearchPositive sentinel nodesSentinel node biopsySentinel nodesPositive nodesAxillary dissectionNode biopsyLower axillary recurrence ratePositive sentinel lymph nodesAxillary recurrence rateNode-positive patientsNeo-adjuvant chemotherapyPercentage of patientsNegative sentinel nodesBreast cancer patientsSentinel lymph nodesEligibility requirementsLumpectomy patientsZ11 trialT4 tumorsPositive patientsLymph nodesRecurrence ratePatient populationCancer patientsInstitutional databaseCharacteristics of multifocal and multicentric breast cancers detetected by preoperative MRI.
Killelea B, Grube B, Philpotts L, Sowden M, Horowitz N, Lannin D. Characteristics of multifocal and multicentric breast cancers detetected by preoperative MRI. Journal Of Clinical Oncology 2011, 29: 67-67. DOI: 10.1200/jco.2011.29.27_suppl.67.Peer-Reviewed Original ResearchBreast cancer patientsSecond tumorPreoperative MRISecond malignanciesPR statusCancer patientsBreast cancerER/PR statusMulticentric breast cancerSuspicious MRI findingsNumber of patientsDiagnosis of cancerLobular histologyNodal statusContralateral breastMRI findingsNode positiveTumor characteristicsTumor sizeHER2 statusAdditional tumorsSecondary lesionsSecondary tumorsPatientsControl group
2004
Is breast-conserving therapy in the genetically predisposed breast cancer patient a reasonable and appropriate option?
Haffty B, Lannin D. Is breast-conserving therapy in the genetically predisposed breast cancer patient a reasonable and appropriate option? European Journal Of Cancer 2004, 40: 1105-1108. PMID: 15110872, DOI: 10.1016/j.ejca.2004.01.032.Peer-Reviewed Original Research